Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023 - Seite 2

Please click here for full Prescribing Information.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

###

The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A. to Salix Pharmaceuticals and its affiliates.

©2023 Salix Pharmaceuticals or its affiliates.

SAL.0074.USA.23

Investor Contact:		Media Contact:
Mark Maico		Kevin Wiggins
[e-mail]		[e-mail]
[phone] (toll free)		[phone]

SOURCE: Salix Pharmaceuticals

View source version on accesswire.com:
https://www.accesswire.com/761778/Salix-to-Present-Data-from-XIFAXANR- ...


The Bausch Health Companies Stock at the time of publication of the news with a fall of -3,12 % to 6,644EUR on Tradegate stock exchange (16. Juni 2023, 22:26 Uhr).